Rockville-based BeneVir Biopharm Inc., a biotech specializing in immunotherapy treatments for cancer, has reached a deal to sell to pharmaceutical goliath Janssen Biotech Inc., a Johnson & Johnson company, in a deal worth up to $1.04 billion. Janssen, based in Titusville, New Jersey, will pay BeneVir $140 million in cash upon closing of the transaction, expected in the second quarter of this year, according to a company announcement. Additional contingent payments based on the achievement of certain…
from https://www.bizjournals.com/baltimore/news/2018/05/08/md-biotech-to-be-acquired-by-new-jersey.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/173710877822
No comments:
Post a Comment